D
X4 Pharmaceuticals, Inc. XFOR
$0.4558 -$0.1095-19.37%
Recommendation
Sell
Prev Close
$0.5653
Volume
3,828,043
Avg Vol (90D)
2,795,771
Market Cap
$96.41M
Dividend & Yield
--
52-Week Range
$0.2612 - $1.60
P/E (TTM)
--
EPS (TTM)
-$0.0877
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
X4 Pharmaceuticals (NASDAQ:XFOR) Earns "Buy" Rating from HC Wainwright
1/14/2025 - MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Stock Holdings Boosted by Jane Street Group LLC
1/14/2025 - Ticker Report
Analysts Have Conflicting Sentiments on These Healthcare Companies: Travere Therapeutics (TVTX), Treace Medical Concepts (TMCI) and X4 Pharmaceuticals (XFOR)
1/14/2025 - TipRanks Financial Blog
Stifel Nicolaus Remains a Buy on X4 Pharmaceuticals (XFOR)
1/14/2025 - TipRanks Financial Blog
X4 Pharmaceuticals, Norgine enter exclusive licensing agreement for Mavorixafor
1/13/2025 - Seeking Alpha - Healthcare
X4 Pharmaceuticals Partners with Norgine for Mavorixafor Expansion
1/13/2025 - TipRanks Financial Blog
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize ...
1/13/2025 - GuruFocus
X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize Mavorixafor in Europe, Australia, and New Zealand
1/13/2025 - Globe Newswire
Brokers Set Expectations for XFOR FY2024 Earnings
1/9/2025 - MarketBeat
Barclays PLC Has $185,000 Stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)
1/8/2025 - Ticker Report
Verition Fund Management LLC Invests $30,000 in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)
12/18/2024 - Ticker Report
Point72 Asset Management L.P. Grows Stake in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)
12/13/2024 - Ticker Report
X4 Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XFOR)
12/12/2024 - Ticker Report
X4 Pharmaceuticals to present on Phase 3 study of Mavorixafor
12/4/2024 - The Fly
X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in ...
12/4/2024 - GuruFocus
X4 Pharmaceuticals to Present Trial-in-Progress Poster on Phase 3 Study of Mavorixafor in Chronic Neutropenia at 66th ASH Annual Meeting and Exposition
12/4/2024 - Globe Newswire
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3/2024 - GuruFocus
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/3/2024 - Globe Newswire
X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference
11/26/2024 - GuruFocus
X4 Pharmaceuticals to Participate in the 36th Annual Piper Sandler Healthcare Conference
11/26/2024 - Globe Newswire
GSA Capital Partners LLP Takes Position in X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)
11/23/2024 - Ticker Report
X4 Pharmaceuticals (NASDAQ:XFOR) Given New $4.00 Price Target at Stifel Nicolaus
11/18/2024 - Ticker Report
HC Wainwright Cuts X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $1.50
11/18/2024 - Ticker Report
Research Analysts Set Expectations for XFOR FY2024 Earnings
11/18/2024 - MarketBeat - AP News
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
11/14/2024 - Globe Newswire
Income Statement
Total Revenue (TTM)
$1.12M
EBITDA (TTM)
-$130.30M
EBIT (TTM)
-$130.89M
Net Income (TTM)
-$16.76M
Balance Sheet
Total Assets (Q)
$178.17M
Total Debt (Q)
$78.20M
Total Liabilities (Q)
$118.54M
Book Value Per Share (Q)
$0.3538
Cash Flow
Cash from Operations (TTM)
-$125.65M
Cash from Investing (TTM)
$70.78M
Cash from Financing (TTM)
$20.26M
Net Change in Cash (TTM)
-$34.40M
Filings
Filing Date
Wednesday, November 13, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Mar 17 and 21 (est)
Price History
Loading...
Beta
2.01
7-Day Total Return
-39.39%
30-Day Total Return
17.05%
60-Day Total Return
-14.48%
90-Day Total Return
-33.35%
Year to Date Total Return
-39.39%
1-Year Total Return
-42.47%
2-Year Total Return
-61.70%
3-Year Total Return
-78.19%
5-Year Total Return
-95.41%
52-week Low
Nov 13, 2024 - $0.2612
52-week High
Mar 26, 2024 - $1.60
Valuation
Market Cap
$96.41M - Micro Cap
Enterprise Value
$39.64M
Price/Sales (TTM)
102.78
Price/Book (Q)
1.60
Dividends and Shares
Shares Outstanding
200.87M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.x4pharma.com
Phone Number
857 529 8300
Address
61 North Beacon Street
Boston, MA 02134
Country
United States
Year Founded
--
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases... more
NASDAQ 01/14/2025 4:00PM Eastern Quotes delayed
Weiss Ratings